-

Cardialen Awarded $2.8 Million Federal Grant to Advance Therapy Designed to Treat Dangerous Heart Rhythms

National Institutes of Health grant will support Cardialen’s development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke.

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has been awarded a $2.8 million National Institutes of Health (NIH) Phase II SBIR grant to further the clinical study of Cardialen’s innovative, low-energy cardioversion of atrial fibrillation (AF) in human subjects in the United States. The grant was awarded after an expert panel of cardiologists, scientists, and engineers gave the Cardialen therapy an exceptional peer review as part of a highly competitive grant process.

Dr. John Hummel, a leading clinical researcher at The Ohio State University Wexner Medical Center specializing in the treatment of atrial fibrillation, is the principal investigator (PI) of this NIH-funded, multi-center clinical study. “Atrial fibrillation remains a serious arrhythmia, and additional treatment options are needed,” said Dr. Hummel. “The early positive results from Cardialen’s acute clinical study are very promising. I am pleased to be the PI for this important study, which is designed to evaluate therapeutic safety and efficacy in an acute clinical setting.”

Atrial fibrillation is an irregular and rapid heart rate that can lead to patient discomfort and increased risk of stroke. Approximately 34 million patients suffer from this condition worldwide.1 Approximately 26% of ICD patients2 and 36% of CRT-D patients3 receiving an implantable cardiac defibrillator have, or will likely experience, atrial fibrillation. Cardialen seeks to provide a therapy for those patients already receiving an implantable defibrillator device.

About Cardialen

Cardialen, Inc. is a Minneapolis-based medical device company developing implantable, low-energy defibrillation and cardioversion therapy designed to treat dangerously fast heart rhythms, including ventricular tachycardia and ventricular fibrillation, in addition to treating atrial fibrillation. Cardialen’s MultiPulse Therapy™ (MPT™) uses a patented sequence of low-energy pulses to restore normal heart rhythm more gently than high-energy, often painful, shocks used for atrial fibrillation and ventricular fibrillation. Learn more at www.cardialen.com.

CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only.

References:

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837-847. doi:10.1161/CIRCULATIONAHA.113.005119

2. Mustafa U, Dherange P, Reddy R, et al. Atrial Fibrillation Is Associated With Higher Overall Mortality in Patients With Implantable Cardioverter‐Defibrillator: A Systematic Review and Meta‐Analysis. J Am Heart Assoc. 2018;7(22). doi:10.1161/JAHA.118.010156

3. Mustafa U, Atkins J, Mina G, et al. Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: A systematic review and meta-analysis of observational studies. Open Hear. 2019;6(1):1-12. doi:10.1136/openhrt-2018-000937

Contacts

Michael Walsh
612-718-8952
Michael@MichaelWalshCommunications.com

Industry:

Cardialen, Inc.

Details
Headquarters: Minneapolis, Minnesota
CEO: Jeff Peters
Employees: 6
Organization: PRI
Release Summary
Cardialen awarded $2.8 million National Institutes of Health grant.
Release Versions
English
Hashtags
#Cardialen

Contacts

Michael Walsh
612-718-8952
Michael@MichaelWalshCommunications.com

More News From Cardialen, Inc.

Cardialen Receives FDA Approval to Conduct Clinical Trial of Low-Energy Atrial Fibrillation Treatment

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a clinical trial of its MultiPulse™ Therapy (MPT™) to treat paroxysmal and persistent atrial fibrillation (AF). MPT is delivered as a sequence of low-energy electrical pulses designed to restore abnormally rapid heart rates, such as AF, to a normal rhythm in a manner potentially less painful to the patient. This FDA-approved...

Cardialen Awarded $3 Million Federal Grant to Advance Therapy Designed to Treat Atrial Fibrillation for Improved Heart Failure Outcomes

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has been awarded a $3 million National Institutes of Health (NIH) Phase IIb SBIR grant for the development of an implantable, low-energy therapy for the cardioversion of atrial fibrillation (AF). The grant was awarded after an expert panel of cardiologists, scientists, and engineers gave the Cardialen therapy an exceptional peer review as part of a highly competitive grant process. Professor Prash Sanders, Director of the Centre for Heart Rhythm Di...

Cardialen Announces Positive Results from Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has published a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology titled Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation. The study consisted of 42 patients who were indicated for AF ablation. In the efficacy portion of the study, MPT achieved 71% termination of AF episodes at energy levels deemed to be tolerable for patients (interquartile range of 0.14 to 1.21 Joules). Dr....
Back to Newsroom